AVROBIO, Inc. (AVRO): Price and Financial Metrics


AVROBIO, Inc. (AVRO)

Today's Latest Price: $13.50 USD

0.30 (-2.17%)

Updated Dec 2 6:55pm

Add AVRO to Watchlist
Sign Up

Overall POWR Rating


POWR Components:

 Trade Grade  Buy & Hold Grade  Peer Grade  Industry Rank


Industry Rank:

Ranked of 389 in Biotech

See all "A" rated Strong Buy stocks

AVRO Stock Price Chart Interactive Chart >

Price chart for AVRO

AVRO Price/Volume Stats

Current price $13.50 52-week high $29.32
Prev. close $13.80 52-week low $9.76
Day low $13.27 Volume 576,400
Day high $13.84 Avg. volume 295,631
50-day MA $14.95 Dividend yield N/A
200-day MA $16.60 Market Cap 492.09M

AVROBIO, Inc. (AVRO) Company Bio


AVROBIO, Inc., a clinical stage gene therapy company, focuses on developing potentially curative ex vivo lentiviral-based gene therapies to treat rare diseases following a single dose. It lead product candidate in AVR-RD-01, which is in Phase 1 clinical trial for the treatment of Fabry disease. The company is also developing AVR-RD-02 for the treatment of Gaucher disease; AVR-RD-03 for the treatment of Pompe disease; and AVR-RD-04 for the treatment of cystinosis. The company was founded in 2015 and is based in Cambridge, Massachusetts.


AVRO Latest News Stream


Event/Time News Detail
Loading, please wait...

AVRO Latest Social Stream


Loading social stream, please wait...

View Full AVRO Social Stream

Latest AVRO News From Around the Web

Below are the latest news stories about AVROBIO Inc that investors may wish to consider to help them evaluate AVRO as an investment opportunity.

Protalix Could Claim Substantial Global Market Share In Fabry Disease

On May 28th, 2020, Protalix BioTherapeutics (PLX) and its commercial partner, Chiesi Global Rare Diseases, announced the submission of their Biologics License Application (BLA) to the U.S. Food and Drug Administration (FDA) for pegunigalsidase alfa for the treatment of adult patients with Fabry disease via the FDA's Accelerated Approval pathway....

Ari Zoldan on Seeking Alpha | October 1, 2020

AVROBIO Receives Orphan Drug Designation from the European Medicines Agency for AVR-RD-02, an Investigational Gene Therapy for Gaucher Disease

CAMBRIDGE, Mass.--(BUSINESS WIRE)---- $AVRO--AVROBIO, Inc. (Nasdaq: AVRO), a leading clinical-stage gene therapy company with a mission to free people from a lifetime of genetic disease, today announced that the European Commission (EC) has granted orphan drug designation for AVR-RD-02, the company’s investigational gene therapy for the treatment of Gaucher disease. AVR-RD-02 consists of the patient’s own hematopoietic stem cells, genetically modified to express glucocerebrosidase (GCase), the enzyme tha

Business Wire | September 28, 2020

AVROBIO (AVRO) Presents At 18th Annual Global Healthcare Virtual Conference - Slideshow

The following slide deck was published by AVROBIO, Inc. in conjunction with this event....

SA Transcripts on Seeking Alpha | September 14, 2020

AVROBIO to Present at Three Upcoming Investor Conferences

CAMBRIDGE, Mass.--(BUSINESS WIRE)---- $AVRO--AVROBIO, Inc. (Nasdaq: AVRO), a leading clinical-stage gene therapy company with a mission to free people from a lifetime of genetic disease, today announced that members of its senior management team are scheduled to participate in three upcoming virtual investor conferences. Citi’s 15th Annual BioPharma Virtual Conference Date: Wednesday, Sept. 9, 2020 2020 Wells Fargo Virtual Healthcare Conference Date: Thursday, Sept. 10, 2020 Time: 4:40 p.m. ET Morgan Sta

Business Wire | September 3, 2020

AVROBIO Reports Second Quarter 2020 Financial Results and Provides Business Update

CAMBRIDGE, Mass.--(BUSINESS WIRE)---- $AVRO--AVROBIO, Inc. (Nasdaq:AVRO), a leading clinical-stage gene therapy company with a mission to free people from a lifetime of genetic disease, today reported financial results for the second quarter ended June 30, 2020 and provided a business update. “We have continued to progress our clinical trials despite the challenges of the COVID-19 global pandemic and have now dosed 12 patients across four clinical trials, with initial data from the first patient dosed in

Business Wire | August 6, 2020

Read More 'AVRO' Stories Here

AVRO Price Returns

1-mo -12.96%
3-mo -17.78%
6-mo -40.89%
1-year -22.24%
3-year N/A
5-year N/A
YTD -32.94%
2019 20.90%
2018 N/A
2017 N/A
2016 N/A
2015 N/A

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!



Page generated in 0.8767 seconds.